These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 38383218)

  • 21. Gene therapy for monogenic liver diseases: clinical successes, current challenges and future prospects.
    Baruteau J; Waddington SN; Alexander IE; Gissen P
    J Inherit Metab Dis; 2017 Jul; 40(4):497-517. PubMed ID: 28567541
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Advances in gene therapy for hemophilia: basis, current status, and future perspectives.
    Ohmori T
    Int J Hematol; 2020 Jan; 111(1):31-41. PubMed ID: 30083852
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gene Therapy Approaches for the Treatment of Hemophilia B.
    Soroka AB; Feoktistova SG; Mityaeva ON; Volchkov PY
    Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445943
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-Term Follow-Up of the First in Human Intravascular Delivery of AAV for Gene Transfer: AAV2-hFIX16 for Severe Hemophilia B.
    George LA; Ragni MV; Rasko JEJ; Raffini LJ; Samelson-Jones BJ; Ozelo M; Hazbon M; Runowski AR; Wellman JA; Wachtel K; Chen Y; Anguela XM; Kuranda K; Mingozzi F; High KA
    Mol Ther; 2020 Sep; 28(9):2073-2082. PubMed ID: 32559433
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term safety and efficacy following systemic administration of a self-complementary AAV vector encoding human FIX pseudotyped with serotype 5 and 8 capsid proteins.
    Nathwani AC; Rosales C; McIntosh J; Rastegarlari G; Nathwani D; Raj D; Nawathe S; Waddington SN; Bronson R; Jackson S; Donahue RE; High KA; Mingozzi F; Ng CY; Zhou J; Spence Y; McCarville MB; Valentine M; Allay J; Coleman J; Sleep S; Gray JT; Nienhuis AW; Davidoff AM
    Mol Ther; 2011 May; 19(5):876-85. PubMed ID: 21245849
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and activity of an engineered, liver-tropic adeno-associated virus vector expressing a hyperactive Padua factor IX administered with prophylactic glucocorticoids in patients with haemophilia B: a single-centre, single-arm, phase 1, pilot trial.
    Xue F; Li H; Wu X; Liu W; Zhang F; Tang D; Chen Y; Wang W; Chi Y; Zheng J; Du Z; Jiang W; Zhong C; Wei J; Zhu P; Fu R; Liu X; Chen L; Pei X; Sun J; Cheng T; Yang R; Xiao X; Zhang L
    Lancet Haematol; 2022 Jul; 9(7):e504-e513. PubMed ID: 35598604
    [TBL] [Abstract][Full Text] [Related]  

  • 27. AAV liver expression of FIX-Padua prevents and eradicates FIX inhibitor without increasing thrombogenicity in hemophilia B dogs and mice.
    Crudele JM; Finn JD; Siner JI; Martin NB; Niemeyer GP; Zhou S; Mingozzi F; Lothrop CD; Arruda VR
    Blood; 2015 Mar; 125(10):1553-61. PubMed ID: 25568350
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gene therapy in an era of emerging treatment options for hemophilia B.
    Monahan PE
    J Thromb Haemost; 2015 Jun; 13 Suppl 1(0 1):S151-60. PubMed ID: 26149016
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CRISPR/Cas9-mediated genome editing via postnatal administration of AAV vector cures haemophilia B mice.
    Ohmori T; Nagao Y; Mizukami H; Sakata A; Muramatsu SI; Ozawa K; Tominaga SI; Hanazono Y; Nishimura S; Nureki O; Sakata Y
    Sci Rep; 2017 Jun; 7(1):4159. PubMed ID: 28646206
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comprehensive analysis and prediction of long-term durability of factor IX activity following etranacogene dezaparvovec gene therapy in the treatment of hemophilia B.
    Shah J; Kim H; Sivamurthy K; Monahan PE; Fries M
    Curr Med Res Opin; 2023 Feb; 39(2):227-237. PubMed ID: 36285399
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Functions of AAV-CMV-F.IX And AAV-EF1alpha-F.IX in gene therapy for hemophilia B.
    Wiwanitkit V
    Hum Gene Ther; 2007 Feb; 18(2):89-92. PubMed ID: 17266422
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sustained delivery of therapeutic concentrations of human clotting factor IX--a comparison of adenoviral and AAV vectors administered in utero.
    Schneider H; Mühle C; Douar AM; Waddington S; Jiang QJ; von der Mark K; Coutelle C; Rascher W
    J Gene Med; 2002; 4(1):46-53. PubMed ID: 11828387
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hemophilia gene therapy-New country initiatives.
    Reiss UM; Zhang L; Ohmori T
    Haemophilia; 2021 Feb; 27 Suppl 3():132-141. PubMed ID: 32638467
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Progress towards gene therapy for haemophilia B.
    Patel N; Reiss U; Davidoff AM; Nathwani AC
    Int J Hematol; 2014 Apr; 99(4):372-6. PubMed ID: 24500177
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Potential limits of AAV-based gene therapy with the use of new transgenes expressing factor IX fusion proteins.
    Le Quellec S; Dane A; Enjolras N; McIntosh J; Rosales C; Negrier C; Nathwani A
    Haemophilia; 2019 Jan; 25(1):e11-e18. PubMed ID: 30520547
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development of a Clinical Candidate AAV3 Vector for Gene Therapy of Hemophilia B.
    Brown HC; Doering CB; Herzog RW; Ling C; Markusic DM; Spencer HT; Srivastava A; Srivastava A
    Hum Gene Ther; 2020 Oct; 31(19-20):1114-1123. PubMed ID: 32657150
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Advances in Gene Therapy for Hemophilia.
    Nathwani AC; Davidoff AM; Tuddenham EGD
    Hum Gene Ther; 2017 Nov; 28(11):1004-1012. PubMed ID: 28835123
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adeno-Associated Virus Gene Therapy for Hemophilia.
    Samelson-Jones BJ; George LA
    Annu Rev Med; 2023 Jan; 74():231-247. PubMed ID: 36103998
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Improved induction of immune tolerance to factor IX by hepatic AAV-8 gene transfer.
    Cooper M; Nayak S; Hoffman BE; Terhorst C; Cao O; Herzog RW
    Hum Gene Ther; 2009 Jul; 20(7):767-76. PubMed ID: 19309290
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term safety and efficacy of factor IX gene therapy in hemophilia B.
    Nathwani AC; Reiss UM; Tuddenham EG; Rosales C; Chowdary P; McIntosh J; Della Peruta M; Lheriteau E; Patel N; Raj D; Riddell A; Pie J; Rangarajan S; Bevan D; Recht M; Shen YM; Halka KG; Basner-Tschakarjan E; Mingozzi F; High KA; Allay J; Kay MA; Ng CY; Zhou J; Cancio M; Morton CL; Gray JT; Srivastava D; Nienhuis AW; Davidoff AM
    N Engl J Med; 2014 Nov; 371(21):1994-2004. PubMed ID: 25409372
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.